Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Joseph W Kim
Yale University Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Los Angeles General Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Keck Medical Center of Usc Pasadena
Pasadena, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Smilow Cancer Center/yale-New Haven Hospital
New Haven, Connecticut, United States
- Yale University
New Haven, Connecticut, United States
- Northwestern University
Chicago, Illinois, United States
- University of Kansas Clinical Research Center
Fairway, Kansas, United States
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
- Nebraska Medicine-Bellevue
Bellevue, Nebraska, United States
- Nebraska Medicine-Village Pointe
Omaha, Nebraska, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, United States
- Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
- Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Aug 2017
- Primary completion
- 6 Oct 2020
- Completion
- 12 Nov 2026
- Last update posted
- 13 May 2026
- Registered enrollment
- 17
- Registry id
- NCT03047213
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.